Hamza Suria
Vorstandsvorsitzender bei Trotana, Inc.
Aktive Positionen von Hamza Suria
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Trotana, Inc.
Trotana, Inc. BiotechnologyHealth Technology Trotana, Inc. discovers and develops medicines. The company is based in San Diego, CA. The CEO of the company is Hamza Suria. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Hamza Suria
Ehemalige bekannte Positionen von Hamza Suria
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ANAPTYSBIO, INC. | Direktor/Vorstandsmitglied | 01.07.2011 | 20.03.2022 |
Vorstandsvorsitzender | 01.07.2011 | 20.03.2022 | |
Corporate Officer/Principal | 01.01.2009 | 01.06.2011 | |
Präsident | 01.07.2011 | 20.03.2022 | |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Corporate Officer/Principal | - | - |
Diabetogen Biosciences, Inc. | Corporate Officer/Principal | - | - |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - | - |
Ausbildung von Hamza Suria
Kalamazoo College | Undergraduate Degree |
University of Western Ontario | Graduate Degree |
Mercersburg Academy | Undergraduate Degree |
Richard Ivey School of Business | Masters Business Admin |
Statistik
International
Vereinigte Staaten | 6 |
Kanada | 4 |
Hong Kong | 2 |
Operativ
Corporate Officer/Principal | 4 |
Chief Executive Officer | 2 |
Undergraduate Degree | 2 |
Sektoral
Consumer Services | 5 |
Health Technology | 4 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ANAPTYSBIO, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Viron Therapeutics, Inc.
Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
Diabetogen Biosciences, Inc. | |
Trotana, Inc.
Trotana, Inc. BiotechnologyHealth Technology Trotana, Inc. discovers and develops medicines. The company is based in San Diego, CA. The CEO of the company is Hamza Suria. | Health Technology |
- Börse
- Insiders
- Hamza Suria
- Erfahrung